Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 (NDUFA13) is an accessory subunit of mitochondrial Complex I, the largest enzyme of the electron transport chain responsible for ATP generation by oxidative phosphorylation[1][2][3]. While not directly involved in catalysis, NDUFA13 is critical for the proper assembly and stability of Complex I, ensures electron transfer from NADH to ubiquinone, and supports mitochondrial membrane potential[1][3]. Also known as GRIM-19, it is implicated in cell death regulation, immune defense (particularly mucosal response to bacteria), and inhibition of STAT3-mediated transcription[1][2][3]. Its altered expression is linked to diseases including inflammatory bowel disease and possibly disorders involving mitochondrial dysfunction or apoptosis[1]. Flurpiridaz F-18 is an approved inhibitor that targets this protein, while NADH interacts physiologically as a substrate[3].
Inhibition of electron transfer (by Flurpiridaz F-18) and modulation of Complex I activity affecting ATP production and cell viability.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 (NDUFA13).